The latest report by IMARC Group, titled “Uveitis Treatment Market Report by Treatment Type (Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal, Analgesics), Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Panuveitis), Cause (Infectious, Non-infectious), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2025-2033,” finds that the global uveitis treatment market size reached USD 1.8 Billion in 2024. Uveitis refers to a condition that causes inflammation of the middle layer of tissue in the eyewall uvea. It causes swelling that can damage the eye tissues, leading to poor vision or blindness. Uveitis is mainly caused by autoimmune diseases in which the body attacks itself, causing inflammation, infection and tumor in the eyes or other parts of the body. The treatment for uveitis involves a therapeutic process that can heal the inflammation of the uvea and surrounding tissues. It is treated with the help of drugs such as cycloplegic agents, anti-inflammatory, antimicrobials, as well as immunotherapy and targeted therapies. Uveitis treatment also provides the patient with relief from the pain, prevents further damage of the tissues, and restores vision loss.
Global Uveitis Treatment Market Trends:
The market is driven by the increasing prevalence of uveitis and other infectious eye disorders in individuals. Besides this, the growing awareness regarding the need for proper treatment among patients is also encouraging the adoption of advanced therapeutics. In addition to this, the rising complication associated with uveitis has resulted in increased investment in healthcare, thereby fueling the market growth. Furthermore, individualswith diabetes, eye injuries, cataracts, glaucoma, band keratopathy, and inflammatory disorders are more susceptible to uveitis. As a result, governments of different nations are taking initiatives to accelerate the approval of drugs in the pipeline and new routes of drug administration to improve the efficacy of the drugs. In addition to this, there has been a rise in the number of clinical trials for eye inflammation treatments for refractory posterior and intermediate uveitis across the globe. Nowadays, several leading manufacturers have increased their production capacity of the medication. Moreover, extensive research and development (R&D) activities in the field of ophthalmology have led to the introduction ofadvanced uveitis treatment, creating lucrative opportunities in the market. Looking forward, the market value is projected to reach USD 2.7 Billion by 2033, expanding at a CAGR of 4.44% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Treatment Type, Disease Type, Cause, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc. and Santen Pharmaceutical Co. Ltd. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800